Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 225, 10.3322/caac.20006 Davies, 2006, Increasing incidence of thyroid cancer in the United States, 1973–2002, JAMA, 295, 2164, 10.1001/jama.295.18.2164 Enewold, 2009, Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005, Cancer Epidemiol Biomarkers Prev, 18, 784, 10.1158/1055-9965.EPI-08-0960 Chen, 2009, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005, Cancer, 115, 3801, 10.1002/cncr.24416 Hundahl, 1998, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995, Cancer, 83, 2638, 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 Burgess, 2002, Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982–1997), Thyroid, 12, 141, 10.1089/105072502753522374 Scheiden, 2006, Thyroid cancer in Luxembourg: a national population-based data report (1983–1999), BMC Cancer, 6, 102, 10.1186/1471-2407-6-102 Gomez Segovia, 2004, Thyroid, 14, 277, 10.1089/105072504323030933 Pingitore, 1993, Pathologica, 85, 591 Shomaf, 2006, New trends in the clinicopathological features of differentiated thyroid cancer in Central Jordan, Saudi Med J, 27, 185 Kihara, 2004, Prognostic factors of anaplastic thyroid carcinoma, Surg Today, 34, 394, 10.1007/s00595-003-2737-6 Brownlie, 2008, Thyroid malignancies: a New Zealand South Island thyroid clinic experience 1995–2006, N Z Med J, 121, 36 Agrawal, 1996, Histologic trends in thyroid cancer 1969–1993: a clinico-pathologic analysis of the relative proportion of anaplastic carcinoma of the thyroid, J Surg Oncol, 63, 251, 10.1002/(SICI)1096-9098(199612)63:4<251::AID-JSO7>3.0.CO;2-B Hadar, 1993, Anaplastic carcinoma of the thyroid, Eur J Surg Oncol, 19, 511 Netea-Maier, 2008, Trends in incidence and mortality of thyroid carcinoma in The Netherlands between 1989 and 2003: correlation with thyroid fine-needle aspiration cytology and thyroid surgery, Int J Cancer, 123, 1681, 10.1002/ijc.23678 Passler, 1999, Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis, Langenbecks Arch Surg, 384, 284, 10.1007/s004230050205 Dijkstra, 2007, Changing patterns of thyroid carcinoma, Ir J Med Sci, 176, 87, 10.1007/s11845-007-0041-y Ito, 2008, Prognosis of patients with papillary carcinoma showing anaplastic transformation in regional lymph nodes that were curatively resected, Endocrin J, 55, 985, 10.1507/endocrj.K08E-148 Zivaljevic, 2008, Case-control study of anaplastic thyroid cancer: goiter patients as controls, Eur J Cancer Prev, 17, 111, 10.1097/CEJ.0b013e3281108036 Smallridge, 2009, Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies, Endocrin Relat Cancer, 16, 17, 10.1677/ERC-08-0154 Ricarte-Filho, 2009, Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1, Cancer Res, 69, 4885, 10.1158/0008-5472.CAN-09-0727 Rodrigues, 2007, Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines, Br J Cancer, 96, 1237, 10.1038/sj.bjc.6603578 Lee, 2008, Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma, Endocrin Relat Cancer, 15, 801, 10.1677/ERC-08-0018 Liu, 2008, Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways, Thyroid, 18, 853, 10.1089/thy.2007.0357 Calin, 2006, MicroRNA signatures in human cancers, Nat Rev Cancer, 6, 857, 10.1038/nrc1997 Visone, 2007, MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle, Endocrin Relat Cancer, 14, 791, 10.1677/ERC-07-0129 Visone, 2007, Specific microRNAs are downregulated in human thyroid anaplastic carcinomas, Oncogene, 26, 7590, 10.1038/sj.onc.1210564 Mitomo, 2008, Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines, Cancer Sci, 99, 280, 10.1111/j.1349-7006.2007.00666.x Takakura, 2008, Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells, Cancer Sci, 99, 1147, 10.1111/j.1349-7006.2008.00800.x Griffith, 2006, Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers, J Clin Oncol, 24, 5043, 10.1200/JCO.2006.06.7330 Onda, 2004, Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes, Endocrin Relat Cancer, 11, 843, 10.1677/erc.1.00818 Montero-Conde, 2008, Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information, Oncogene, 27, 1554, 10.1038/sj.onc.1210792 Schweppe, 2008, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification, J Clin Endocrinol Metab, 93, 4331, 10.1210/jc.2008-1102 Marlow, 2009, Reactivation of suppressed RhoB is a critical step for inhibition of anaplastic thyroid cancer growth, Cancer Res, 69, 1536, 10.1158/0008-5472.CAN-08-3718 Francipane, 2009, Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy, Cancer Res, 69, 6141, 10.1158/0008-5472.CAN-09-0994 Kebebew, 2005, Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors, Cancer, 103, 1330, 10.1002/cncr.20936 Yau, 2008, Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy, Ann Surg Oncol, 15, 2500, 10.1245/s10434-008-0005-0 Pierie, 2002, The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma, Ann Surg Oncol, 9, 57, 10.1245/aso.2002.9.1.57 Besic, 2005, Prognostic factors in anaplastic carcinoma of the thyroid—a multivariate survival analysis of 188 patients, Langenbecks Arch Surg, 390, 203, 10.1007/s00423-004-0524-5 Venkatesh, 1990, Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases, Cancer, 66, 321, 10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A Dandekar, 2009, Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis, Int J Radiat Oncol Biol Phys, 74, 518, 10.1016/j.ijrobp.2008.08.016 Bhatia, 2009, Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy, Head Neck, 10.1002/hed.21257 Tan, 1995, Anaplastic carcinoma of the thyroid: a 24-year experience, Head Neck, 17, 41, 10.1002/hed.2880170109 Kobayashi, 1996, Treatment of 37 patients with anaplastic carcinoma of the thyroid, Head Neck, 18, 36, 10.1002/(SICI)1097-0347(199601/02)18:1<36::AID-HED5>3.0.CO;2-# McIver, 2001, Anaplastic thyroid carcinoma: a 50-year experience at a single institution, Surgery, 130, 1028, 10.1067/msy.2001.118266 Swaak-Kragten, 2009, Multimodality treatment for anaplastic thyroid carcinoma—treatment outcome in 75 patients, Radiother Oncol, 92, 100, 10.1016/j.radonc.2009.02.016 Haigh, 2001, Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival, Cancer, 91, 2335, 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1 Goutsouliak, 2005, Anaplastic thyroid cancer in British Columbia 1985–1999: a population-based study, Clin Oncol (R Coll Radiol), 17, 75, 10.1016/j.clon.2004.07.013 Brignardello, 2007, Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years, Eur J Endocrinol, 156, 425, 10.1530/EJE-06-0677 Junor, 1992, Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy, Eur J Surg Oncol, 18, 83 Voutilainen, 1999, Anaplastic thyroid carcinoma survival, World J Surg, 23, 975, 10.1007/s002689900610 Schlumberger, 1991, Combination therapy for anaplastic giant cell thyroid carcinoma, Cancer, 67, 564, 10.1002/1097-0142(19910201)67:3<564::AID-CNCR2820670306>3.0.CO;2-E De Crevoisier, 2004, Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy, Int J Radiat Oncol Biol Phys, 60, 1137, 10.1016/j.ijrobp.2004.05.032 Wang, 2006, Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens, Cancer, 107, 1786, 10.1002/cncr.22203 Kim, 1987, Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy, Cancer, 60, 2372, 10.1002/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO;2-1 Tennvall, 2002, Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery, Br J Cancer, 86, 1848, 10.1038/sj.bjc.6600361 Levendag, 1993, Anaplastic carcinoma of the thyroid gland treated by radiation therapy, Int J Radiat Oncol Biol Phys, 26, 125, 10.1016/0360-3016(93)90182-U Wong, 1991, Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma, Radiother Oncol, 20, 3, 10.1016/0167-8140(91)90105-P Nutting, 2001, Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland, Radiother Oncol, 60, 173, 10.1016/S0167-8140(01)00382-6 Sugino, 2002, The important role of operations in the management of anaplastic thyroid carcinoma, Surgery, 131, 245, 10.1067/msy.2002.119936 Busnardo, 2000, A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients, J Endocrinol Invest, 23, 755, 10.1007/BF03345066 Shimaoka, 1985, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma, Cancer, 56, 2155, 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E Ain, 2000, Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group, Thyroid, 10, 587, 10.1089/thy.2000.10.587 Cohen, 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study, J Clin Oncol, 26, 4708, 10.1200/JCO.2007.15.9566 Mooney, 2009, A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome, Thyroid, 19, 233, 10.1089/thy.2008.0321 Kloos, 2009, Phase II trial of sorafenib in metastatic thyroid cancer, J Clin Oncol, 27, 1675, 10.1200/JCO.2008.18.2717 Tsimberidou, 2009, Phase I clinical trials in 56 patients with thyroid cancer: the M.D. Anderson Cancer Center experience, J Clin Endocrinol Metab, 94, 4423, 10.1210/jc.2009-0743 Shinohara, 2009, Successful treatment of locally advanced anaplastic thyroid carcinoma by chemotherapy and hyperfractionated radiotherapy, Auris Nasus Larynx, 36, 729, 10.1016/j.anl.2009.02.001 Hogan, 2009, Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib, J Oncol Pharm Pract, 15, 111, 10.1177/1078155208101212 Noguchi, 2009, Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery, Endocrin J, 56, 245, 10.1507/endocrj.K08E-016 Fury, 2007, A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors, Cancer Chemother Pharmacol, 59, 467, 10.1007/s00280-006-0286-6 Dedecjus, 2007, Selective embolization of thyroid arteries as a preresective and palliative treatment of thyroid cancer, Endocrin Relat Cancer, 14, 847, 10.1677/ERC-07-0011 Menon, 2009, Micro-RNAs in thyroid neoplasms:molecular, diagnostic and therapeutic implications, J Clin Pathol, 62, 978, 10.1136/jcp.2008.063909 Schwertheim, 2009, Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma, Horm Metab Res, 41, 475, 10.1055/s-0029-1215593 Deen, 2009, Anaplastic thyroid carcinoma exhibits intratumoral molecular homogeneity for a therapeutic target panel, Anticancer Res, 29, 2437 Elliott, 2008, Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification, Hum Pathol, 39, 15, 10.1016/j.humpath.2007.05.012 Garg, 2009, Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer, J Clin Endocrinol Metab, 94, 4613, 10.1210/jc.2009-0703 Landriscina, 2009, Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype, Thyroid, 19, 629, 10.1089/thy.2008.0355 Papewalis, 2009, Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer, Horm Metab Res, 41, 752, 10.1055/s-0029-1224116 Zhu, 2009, A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway, Mol Pharmacol, 75, 812, 10.1124/mol.108.052605 McLaughlin, 2009, Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis, BMC Cancer, 9, 369, 10.1186/1471-2407-9-369 Kim, 2009, Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells, Mol Cancer Res, 7, 1645, 10.1158/1541-7786.MCR-09-0117 Ooi, 2009, Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib, Clin Cancer Res, 15, 7153, 10.1158/1078-0432.CCR-09-1071 Lam, 2000, Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21, Ann Surg, 231, 329, 10.1097/00000658-200003000-00005 Demeter, 1991, Anaplastic thyroid carcinoma: risk factors and outcome, Surgery, 110, 956 Rodriguez, 2000, Clinical and histological differences in anaplastic thyroid carcinoma, Eur J Surg, 166, 34 Veness, 2004, Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach, ANZ J Surg, 74, 559, 10.1111/j.1445-2197.2004.03062.x Chemotherapy Committee The Japanese Society of Thyroid Surgery, 1995, Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte colony-stimulating factor support, Jpn J Clin Oncol, 25, 203, 10.1093/oxfordjournals.jjco.a039778 Vrbic, 2009, Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience, J BUON, 14, 41 Chen, 2008, Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002, Am J Clin Oncol, 31, 460, 10.1097/COC.0b013e31816a61f3